Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
As a major cause of end stage renal disease IgA nephropathy (IgAN) is a common indication for renal transplant. Despite this, the disease course post transplantation and in particular the implications of recurrence remain unclear. A growing body of evidence suggests an association of disease recurrence with graft failure, and increasing recognition of this issue may impact on future management strategies. We set out to investigate patterns of recurrence and graft failure in patients transplanted for IgAN in Ireland.
Using records from the Irish national transplant registry and local centres, we collated retrospective data for patients transplanted for IgAN between January 2000 and December 2023. Included patients required biopsy evidence of IgAN. This was either in native kidney (n = 267) or where no native kidney biopsy was available, in biopsy of transplant (n = 58). A total of 291 patients met criteria for inclusion and where patients had multiple transplants each graft was separately included for analysis.
Aalen-Johansen competing risks analysis was used to estimate cumulative incidence of graft failure and death for patients with and without histologically confirmed recurrence. Biopsy, both before and after transplant, had been undertaken only if clinically indicated. Chi squared test used to compare cohort of patients with and without biopsy proven recurrence.
Median duration from date of transplant to end of study was 8.9 years (standard deviation 6.8). 120 of 325 transplants were biopsied, of which 92 showed evidence of IgAN recurrence (28% of total). Median time to histological recurrence was 4.9 years. Transplant recipients with recurrent disease were more likely to experience graft failure (p <0.001 by Gray’s test), with estimated 33% (95% CI 23%-43%) incidence of graft failure at 10 years post-transplant compared with 10% (6.0%-16%) in the group without biopsy confirmed recurrence. All-cause mortality was similar between these groups, with a total of 27 deaths recorded in the study population during follow-up. Recurrence cohort had younger age with mean 38.2 years vs 45.0 years in group without recurrence. Donor status was similar with majority of transplants from deceased donors, and no significant difference in proportion of those with organ from living related donor in those with biopsy evidence of recurrence (11%), compared to those without (16%, p = 0.50)
In total, 63 of 325 experienced graft failure, with median time to failure of 7.0 years, and 10 year cumulative incidence of graft failure estimated at 19%.
In conclusion, our data adds to the growing body of evidence suggesting recurrence of IgAN is associated with an increased risk of graft failure. This should be viewed within the confines of lack of protocol biopsy, and the inevitable sampling bias this entails. Further work is ongoing to investigate variables associated with recurrent disease and failure.
